ReviewMedical oncology (Northwood, London, England)2023
Extensive review on breast cancer its etiology, progression, prognostic markers, and treatment.
Review in Medical oncology (Northwood, London, England), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
32 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Pooled it
- Prognostic and clinicopathological significance of fibrinogen-to-albumin ratio (FAR) in patients with breast cancer: a meta-analysis.World journal of surgical oncology · 2024Pooled it
- Association between circadian rhythm-related behaviors and breast cancer: a bidirectional Mendelian randomization study.Future science OA · 2026Article
- Targeting common denominators of DNA damage tolerance mechanisms as therapeutic strategy to cope with dynamic phenotypic changes in triple-negative breast cancer cells.Cell death discovery · 2026Article
- Photodynamic therapy mediated by a selective nanoemulsion for breast cancer treatment: in vitro and in vivo evaluation.Discover nano · 2026Article
- In Vitro Doxorubicin Delivery Using TPP-Folate-Dendrimer-Functionalized Gold Nanoclusters.Pharmaceuticals (Basel, Switzerland) · 2026Article
- Effects of Naringenin in Preclinical Models of Breast Cancer.Biomolecules · 2026Review
- Post-Radiotherapy Changes in Circulating Dodecanoic Acid Identify Metabolic Phenotypes Associated with Recurrence in Breast Cancer.Biomolecules · 2026Article
- Lactoferrin-Conjugated Nanocarriers for Transformative Strategies in Cancer Management: New Insights on Breast Cancer Therapy.Current drug delivery · 2026Review
- Evaluation of genes and molecular pathways involved in ferroptosis in breast cancer: A systems biology and bioinformatics approach.Biochemistry and biophysics reports · 2025Article
- Identification and external validation of a prognostic signature based on myeloid-derived suppressor cells-related LncRNAs to evaluate survival prognosis and treatment efficacy in invasive breast carcinoma.Biochemistry and biophysics reports · 2025Article
- Experiences of weight management during rehabilitation in breast cancer survivors: A qualitative study.Asia-Pacific journal of oncology nursing · 2025Article
- Mushroom Bioactive Molecules as Anticancerous Agents: An Overview.Food science & nutrition · 2025Review
- An explainable AI-driven deep neural network for accurate breast cancer detection from histopathological and ultrasound images.Scientific reports · 2025Article
- Article
- Recent Advancements in Breast Cancer Therapies and Biomarkers: Mechanisms and Clinical Significance.Current pharmaceutical biotechnology · 2025Review
- Response and prognosis to neoadjuvant chemotherapy in women early breast cancer of HER2-low status.Frontiers in oncology · 2025Article
- Translocation of benzo(a)pyrene reactive metabolites across human mammary epithelial cell membranes.PloS one · 2025Article
- Down-Regulation of lncRNA CKMT2-AS1 Predicts Poor Prognosis and Promotes Breast Cancer Progression.Breast cancer (Dove Medical Press) · 2025Article
- Lycorine affects tamoxifen resistance of breast cancer via mTranslational cancer research · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
As the most frequent and vulnerable malignancy among women, breast cancer universally manifests a formidable healthcare challenge. From a biological and molecular perspective, it is a heterogenous disease and is stratified based on the etiological factors driving breast carcinogenesis. Notably, genetic predispositions and epigenetic impacts often constitute the heterogeneity of this disease. Typically, breast cancer is classified intrinsically into histological subtypes in clinical landscapes. These stratifications empower physicians to tailor precise treatments among the spectrum of breast cancer therapeutics. In this pursuit, numerous prognostic algorithms are extensively characterized, drastically changing how breast cancer is portrayed. Therefore, it is a basic requisite to comprehend the multidisciplinary rationales of breast cancer to assist the evolution of novel therapeutic strategies. This review aims at highlighting the molecular and genetic grounds of cancer additionally with therapeutic and phytotherapeutic context. Substantially, it also renders researchers with an insight into the breast cancer cell lines as a model paradigm for breast cancer research interventions.
Indexed as
Identifiers
37442848What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.